Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Akebia's lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB-6548 is being developed as a once-daily oral therapy which works through the inhibition of hypoxia-inducible factor prolyl hydroxylase, leading to stabilization and increased levels of HIFα and therefore improved production of hemoglobin and red blood cells.
Cambridge, US
63 (est)+54%

Akebia Therapeutics Locations

Cambridge, US

Akebia Therapeutics Metrics

Akebia Therapeutics Summary

Founding Date


Market capitalization

$144 M

Closing share price


Akebia Therapeutics Market Value History

Akebia Therapeutics News

Akebia Therapeutics Company Life